In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

Jaehong Key; Christy Cooper; Ah Young Kim; Deepika Dhawan; Deborah W. Knapp; Kwangmeyung Kim; Jae Hyung Park; Kuiwon Choi; Ick Chan Kwon; Kinam Park; James F. Leary

doi:10.1016/j.jconrel.2012.07.038

In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

Jaehong Key, Christy Cooper, Ah Young Kim, Deepika Dhawan, Deborah W. Knapp, Kwangmeyung Kim, Jae Hyung Park, Kuiwon Choi, Ick Chan Kwon, Kinam Park, James F. Leary

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

Original language	English
Pages (from-to)	249-255
Number of pages	7
Journal	Journal of Controlled Release
Volume	163
Issue number	2
DOIs	https://doi.org/10.1016/j.jconrel.2012.07.038
State	Published - 28 Oct 2012

Bibliographical note

Funding Information:
This work was supported by KIST-Purdue GRL (Global Research Laboratory) Collaboration , “Molecular Imaging and Nanomedicine for Theragnosis using NanoBioMaterials”; Grant number: 202979 and the Christopher Columbus Foundation support to JFL. We would like to especially thank Patty I. Bonney, Lindsey M. Fourez, Jane C. Stewart, and Carol Ann Dowell at Purdue University for their assistance with this work. We also express our appreciation to Dr. Aaron Taylor of the Bindley Bioscience Imaging Facility, Dr. Tom Talavage and Greg Tamer of the Purdue MRI facility at Purdue Research Park, and to Debby Sherman and Chia-Ping Huang of the Life Sciences Microscopy Facility at Purdue University for the TEM images, and to Lisa Reece of the Bionano Facility in the Birck Nanotechnology Center supported in part by the Indiana Clinical and Translational Sciences Institute from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award.

Keywords

Cancer
Chitosan nanoparticle
Dual-modality imaging
MRI
NIRF imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jconrel.2012.07.038

Cite this

@article{0600da3f343a44378b4dfc627731d658,

title = "In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles",

abstract = "One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.",

keywords = "Cancer, Chitosan nanoparticle, Dual-modality imaging, MRI, NIRF imaging",

author = "Jaehong Key and Christy Cooper and Kim, {Ah Young} and Deepika Dhawan and Knapp, {Deborah W.} and Kwangmeyung Kim and Park, {Jae Hyung} and Kuiwon Choi and Kwon, {Ick Chan} and Kinam Park and Leary, {James F.}",

note = "Funding Information: This work was supported by KIST-Purdue GRL (Global Research Laboratory) Collaboration , “Molecular Imaging and Nanomedicine for Theragnosis using NanoBioMaterials”; Grant number: 202979 and the Christopher Columbus Foundation support to JFL. We would like to especially thank Patty I. Bonney, Lindsey M. Fourez, Jane C. Stewart, and Carol Ann Dowell at Purdue University for their assistance with this work. We also express our appreciation to Dr. Aaron Taylor of the Bindley Bioscience Imaging Facility, Dr. Tom Talavage and Greg Tamer of the Purdue MRI facility at Purdue Research Park, and to Debby Sherman and Chia-Ping Huang of the Life Sciences Microscopy Facility at Purdue University for the TEM images, and to Lisa Reece of the Bionano Facility in the Birck Nanotechnology Center supported in part by the Indiana Clinical and Translational Sciences Institute from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award. ",

year = "2012",

month = oct,

day = "28",

doi = "10.1016/j.jconrel.2012.07.038",

language = "English",

volume = "163",

pages = "249--255",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

AU - Key, Jaehong

AU - Cooper, Christy

AU - Kim, Ah Young

AU - Dhawan, Deepika

AU - Knapp, Deborah W.

AU - Kim, Kwangmeyung

AU - Park, Jae Hyung

AU - Choi, Kuiwon

AU - Kwon, Ick Chan

AU - Park, Kinam

AU - Leary, James F.

N1 - Funding Information: This work was supported by KIST-Purdue GRL (Global Research Laboratory) Collaboration , “Molecular Imaging and Nanomedicine for Theragnosis using NanoBioMaterials”; Grant number: 202979 and the Christopher Columbus Foundation support to JFL. We would like to especially thank Patty I. Bonney, Lindsey M. Fourez, Jane C. Stewart, and Carol Ann Dowell at Purdue University for their assistance with this work. We also express our appreciation to Dr. Aaron Taylor of the Bindley Bioscience Imaging Facility, Dr. Tom Talavage and Greg Tamer of the Purdue MRI facility at Purdue Research Park, and to Debby Sherman and Chia-Ping Huang of the Life Sciences Microscopy Facility at Purdue University for the TEM images, and to Lisa Reece of the Bionano Facility in the Birck Nanotechnology Center supported in part by the Indiana Clinical and Translational Sciences Institute from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award.

PY - 2012/10/28

Y1 - 2012/10/28

N2 - One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

AB - One difficulty of diagnosing and treating cancer is that it is very challenging to detect cancers in the early stages before metastasis occurs. A variety of imaging modalities needs to be used from non-invasive, moderate resolution modalities, such as magnetic resonance imaging (MRI) to very high-resolution (e.g. fluorescence) imaging that can help guide surgeons during a surgical operation. While MRI can have relatively high resolution and deep penetration to visualize soft tissues, low sensitivity of MRI frequently requires tumor imaging agents to enhance the MRI contrast at the tumor site. At the other end of the resolution spectrum, near infrared fluorescence (NIRF) imaging has very high sensitivity but frequently cannot be utilized for initial human in vivo imaging due to its very limited penetration depth. To combine the advantages of each imaging modality we have constructed MRI and NIRF dual-modality nanoparticles using glycol chitosan, Cy5.5, and superparamagnetic iron oxide nanoparticles (SPIOs). We have demonstrated these advantages for dual-modality, in vivo tumor imaging in mice. Our studies suggest the potential use of NIRF and MR dual modality imaging for human cancer diagnosis.

KW - Cancer

KW - Chitosan nanoparticle

KW - Dual-modality imaging

KW - MRI

KW - NIRF imaging

UR - http://www.scopus.com/inward/record.url?scp=84867632481&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.07.038

DO - 10.1016/j.jconrel.2012.07.038

M3 - Article

C2 - 22902594

AN - SCOPUS:84867632481

SN - 0168-3659

VL - 163

SP - 249

EP - 255

JO - Journal of Controlled Release

JF - Journal of Controlled Release

IS - 2

ER -

In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this